Nathaniel Treister, DMD, DMSc, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, MA, gives an overview of the management of oral graft-versus-host disease (GvHD), where the chronic presentation is more common. The correct diagnosis is the first key step, since it can also provide a systemic diagnosis for GvHD and help determine what treatment is needed. Not in all cases a patient will need systemic therapy, and this may or may not cover the oral treatment needs. The manifestations of the disease need to be understood as the patient may benefit from therapies according to their symptoms. Dental caries and recurring candidiasis, mostly in patients using steroids can also develop, adding complications that may require a holistic approach for both symptoms and the GvHD itself. Finally, long-term follow-up is crucial to monitor secondary carcinomas that could manifest years after first diagnosis. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
